Search results for COST

Open search
Tenzing MEMO publishes independent research you won't find anywhere else. Sign up for a free trial to access everything — including 18 articles published in the last two weeks.
Sign Up
Vertex Pharmaceuticals Incorporated (VRTX)
Locked

The Kidney Franchise the Market Hasn't Priced

The familiar standoff—elite CF monopoly versus a full multiple and a maturing core—resolves in the buyers' favor once you weight the catalysts by how knowable they are. CF is converting toward ALYFTREK on a long exclusivity runway and funding everything else; that is the demon...

Read Article ›
Hawaiian Electric Industries, Inc. (HE)
Locked

The Legal Cliff Is Past, But the Earnings Climb Is Just Starting

Hawaiian Electric has graduated from tail-risk to execution risk, and that is a genuine improvement in the quality of the investment. The legal cliff is behind it: the global settlement is final, the releases are effective, and the first $479 million installment is paid.

Read Article ›
Lumen Technologies, Inc. (LUMN)
Locked

The Solvency Trade Is Over, The Execution Trade Has Just Begun

Lumen is no longer the same company that frightened credit analysts two years ago. Strip away the legacy CenturyLink copper businesses and what remains is an enterprise and wholesale network operator built around three things: a 340,000 route mile fiber backbone, a fast growin...

Read Article ›
Blue Bird Corporation (BLBD)
Locked

An Execution Machine Earns a Premium, A Stock With Room to Run

Blue Bird is a rare niche manufacturer that has beaten guidance fourteen straight quarters, raised its FY2026 outlook twice, and just completed a deal that materially widens its addressable market. At roughly 17x trailing earnings and ~9x forward Adjusted EBITDA, the stock tra...

Read Article ›
Lam Research Corporation (LRCX)
Locked

Three Engines Firing, But the Stock Already Knows It

Lam Research delivered a record March quarter and guided its June quarter to a stunning $6.6 billion in revenue — roughly 10% above consensus at the time. The business is accelerating across memory, foundry, and services. Yet with shares near $318, up close to 300% in the past...

Read Article ›
McKesson Corporation (MCK)
Locked

McKesson's Revenue Miss Is a Mirage

McKesson delivered FY2026 adjusted EPS of $39.11 (+18% year-over-year), beating its own long-range growth targets, and guided FY2027 EPS to $43.80–$44.60 (+12–14%). Q4 revenue of $96.3 billion missed consensus by ~5%, but the miss reflects branded drug price deflation and GLP-...

Read Article ›